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The Genetic Basis of Panic Disorder
Panic disorder is one of the chronic and disabling anxiety disorders. There has been 
evidence for either genetic heterogeneity or complex inheritance, with environmental 
factor interactions and multiple single genes, in panic disorder’s etiology. Linkage studies 
have implicated several chromosomal regions, but no research has replicated evidence for 
major genes involved in panic disorder. Researchers have suggested several 
neurotransmitter systems are related to panic disorder. However, to date no candidate 
gene association studies have established specific loci. Recently, researchers have 
emphasized genome-wide association studies. Results of two genome-wide association 
studies on panic disorder failed to show significant associations. Evidence exists for 
differences regarding gender and ethnicity in panic disorder. Increasing evidence suggests 
genes underlying panic disorder overlap, transcending current diagnostic boundaries. In 
addition, an anxious temperament and anxiety-related personality traits may represent 
intermediate phenotypes that predispose to panic disorder. Future research should focus on 
broad phenotypes, defined by comorbidity or intermediate phenotypes. Genome-wide 
association studies in large samples, studies of gene-gene and gene-environment 
interactions, and pharmacogenetic studies are needed.
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INTRODUCTION
Although more than a century has passed since panic symp-
toms were first described, panic disorder (PD) was not classi-
fied as a separate disorder entity until 1980. According to the 
DSM-IV, PD is defined by recurrent, unexpected panic attacks, 
for more than one month, in association with at least one of the 
following symptoms: persistent concern about having addition-
al attacks, worry about the attacks’ implications and/or conse-
quences, or a significant change in behavior as a result of the 
attacks. 
  Notably, while panic attacks are a defining feature of PD, they 
may also occur as symptoms of phobic disorders or sporadical-
ly in the absence of any anxiety disorder. The estimated lifetime 
prevalence of PD is 4.7%, and the median age of PD onset is 24 
yr (1). However, the lifetime prevalence of isolated panic attacks 
has been estimated at 22.7% (2). 
  PD causes substantial suffering and incurs economic costs to 
both patients and society at large (3). In addition, panic attacks 
are reportedly linked to increased cardiovascular morbidity and 
mortality (4). Therefore, researchers and clinicians should regard 
PD as an important psychiatric disease. However, no genetic 
basis for PD has been clearly defined, though interest and re-
searches in this area are increasing. This article examines PD’s 
genetic basis. We reviewed genetic studies of PD, focusing es-
pecially on genome-wide association studies (GWAS) that re-
searchers have recently carried out regarding many psychiatric 
disorders, which have yielded novel genetic loci for additional 
research.
GENETIC EPIDEMIOLOGY OF PANIC DISORDER
For a long time, family and twin studies have suggested there are 
genetic influences on PD. Linkage analyses and association stud-
ies have become predominant, making up for several limitations 
of family and twin studies. However, they are still not sufficient 
for reaching a clear conclusion regarding PD’s genetic basis. 
Family studies  
Researchers conducted family studies to examine whether a cer-
tain phenotype aggregates in some families, by comparing the 
phenotype prevalence among affected probands’ relatives with 
that of unaffected controls’ relatives. Early in the genetics-based 
research into PD, these studies were widely used to elucidate the 
disorder’s genetic mechanism. Ever since psychiatrists knew PD 
as a family disease, six controlled family studies have document-
ed an increased PD risk (5.7%-17.3%) among affected individu-
als’ relatives (5-10). Furthermore, Goldstein et al. found a 17-fold 
increased PD risk in first-degree relatives of PD probands when 
their onset ages were below 20, whereas the study found only a Na H-R, et al.  •  The Genetic Basis of Panic Disorder
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6-fold increased PD risk in first-degree relatives of probands when 
the onset age exceeded 20 yr (11). A meta-analytic report revealed 
the unadjusted aggregate risk for relatives of PD probands was 
10.0%, compared with 2.1% for control subjects’ relatives (12). 
Although family studies have clearly documented that PD ag-
gregates in some families, these studies have some limitations, 
in that they did not distinguishing genetic contributions from 
environmental factors.
Twin studies
Twin studies, which supplement family studies, can provide ad-
ditional information on the roles of genetic effects and of shared 
and unique environment effects. Twin studies of PD have dem-
onstrated this phenotype is moderately heritable and that the 
concordance rate for monozygotic twins is higher than that for 
dizygotic twins. These findings indicate genetic factors contrib-
ute to PD’s pathogenesis with an estimated heritability of 30%-
40%. A meta-analysis of high-quality twin studies by Hettema 
et al. (12) estimated PD heritability at 0.43. A more recent analy-
sis, by the Virginia Adult Twin Study of Psychiatric and Substance 
Use Disorders, comprising more than 5,000 twins, showed a PD 
heritability of 0.28 (13). Thus, genes clearly contribute to the 
pathogenesis of PD, but environmental influences are also sub-
stantial.  
  Multivariate modeling of twin data suggests little contribu-
tion by the shared environment (i.e., experiences and familial 
factors common to both twins), with most of the variance attrib-
utable to the individual-specific environment, which also in-
cludes the measurement error (12, 13). Although family and 
twin studies provided support for PD’s genetic propensity, they 
did not provide clear evidence of Mendelian inheritance of PD, 
which suggested a single gene’s individual effect may be minor.
LINKAGE ANALYSES
Linkage analysis is a method commonly used to map probable 
genetic loci for specific diseases through observing related in-
dividuals. Allelic heterogeneity does not affect linkage analysis, 
which applies to both monogenetic (parametric linkage) and 
complex disease (model-free or non-parametric linkage) includ-
ing PD. A linkage study’s advantage lies in the lack of any need 
for a priori hypothesis to identify risk loci for a particular dis-
ease. However, its detection sensitivity in complex genetic dis-
eases is rather low, particularly given single genes’ small indi-
vidual effects in complex genetic diseases, such as PD. Several 
groups have undertaken linkage studies to map the relevant loci 
in PD, which have implicated several chromosomal regions, in-
cluding 1q(14), 2q(15), 4q31-q34(16, 17), 7p(18, 19), 9q(17, 20), 
12q(21), 13q(17, 22),14q(17, 23), 15q(15), and 22q(17, 24). How-
ever, linkage anlayses for PD have shown little consistency. 
ASSOCIATION STUDIES
Although linkage analysis has yielded many implications re-
garding PD’s genetic basis, such an analysis has limitations re-
garding complex (non-Mendelian) traits. Association analyses, 
which compare single-locus alleles or genotype frequencies (or, 
more generally, multilocus haplotype frequencies) between dis-
eased subjects and healthy controls, have come to the forefront 
in genetic studies these days. Association analyses aim to iden-
tify the susceptibility loci. Most association studies of PD were 
limited to the candidate gene that was hypothesized to be caus-
ally related to the phenotype. In such a case, the candidate alleles 
should include variants that are either directly related to the phe-
notype or strongly correlated with (i.e., in linkage disequilibri-
um with) such causal variants. Association analyses of PD have 
implicated several genes that are essentially classical candidate 
genes, such as MAOA, COMT, ADORA2A, and CCK-BR. To date, 
association studies of PD have examined more than 350 candi-
date genes, but most results were inconsistent, negative, or not 
clearly replicated. Only the Val158Met polymorphism of the cat-
echol-O-methyltransferase (COMT) gene has been implicated 
in susceptibility to PD by several studies on independent sam-
ples. A recent meta-analysis confirmed this implication. Here, 
we review several PD candidate genes, based on monaminergic 
neurotransmitter systems. Fig. 1 shows various systems that may 
be related to PD. 
Catechol-O-methyltransferase (COMT) 
The COMT gene encodes the protein catechol-O-methyltrans-
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Fig. 1. Brain systems that may be ralated to panic disorder. COMT, catechol-O-methyl-
transferase; 5-HT, 5-hydroxytryptamine; MAO, Monoamine oxidase; CCK, Cholecysto-
kinin; GABA, γ-aminobutyric acid; NPY, neuro  peptide Y. 
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ferase, an enzyme involved in the catabolic breakdown of cate-
cholamines. Anxiety states associate with significantly elevated 
erythrocyte COMT activity (25). The COMT gene is located on 
chromosome 22q11.2. A single-nucleotide polymorphism (472G/ 
A) in the COMT gene causes an amino acid change, at position 
158, from valine to methionine. The gene harbors a DNA poly-
morphism, common across all human populations, that leads 
to alterations in the enzyme’s activity. The COMT 158val allele 
confers higher COMT activity than the COMT 158met allele does 
(25). This polymorphism, variably called Val158Met or rs4680, 
has been examined in a number of studies, using both linkage 
and association paradigms, with samples ranging from as few as 
29 cases to nearly 200 cases. Four of eight studies reported nom-
inally significant findings among 255 cases, 249 controls, 163 
trios, and 70 multiplex pedigrees (26-29) and negative results 
among 361 cases and 1,815 controls (30-33). 
  Several of the positive associations appeared more pronounc-
ed in female subsets of the samples. One subset meta-analysis 
showed no consistent association but did suggest a heteroge-
neity between the findings, possibly driven by ethnicity (34). 
Another meta-analysis suggested the same general conclusion, 
but its authors argued ethnicity- and gender-specific analyses 
supported an association between the Val158Met polymorphism 
and PD (35). Given the multiple positive findings in case-con-
trol studies and family-based association studies, COMT seems 
to be one of the few consistent findings in PD genetics. However, 
the actual associated allele remains unknown, although previ-
ous studies have reported a prominent ethnic heterogeneity in 
the Val158Met SNP’s DNA diversity pattern and the specific al-
lele frequency (36). As mentioned above, the alleles of genes that 
some studies have defined, some different studies have impli-
cated, while yet others have produced negative results, raising 
the risk of false negatives. So, although researchers have con-
ducted a number of association studies, they have identified no 
specific gene as a susceptibility locus. This genetic variation’s 
particular role in PD requires additional analysis, considering 
its gender- and ethnicity-dependent effect and putative impact 
on cognitive functions.
Serotonergic (5-hydroxy-tryptamine [5-HT]) system 
The serotonergic 5-HT system plays an important role in both 
the pathophysiology and treatment of PD. Challenge studies 
with carbon dioxide-induced panic and brain imaging findings 
have shown that the 5-HT system has an association with panic 
symptoms. Also, selective serotonin-reuptake inhibitors are 
used as first-line pharmacological treatments for PD. 
  Tryptophan hydroxylase (TPH), the rate-limiting enzyme in 
5-HT biosynthesis, has two isoforms. TPH1 is mainly responsi-
ble for the synthesis of 5-HT in peripheral organs, and TPH2, in 
the central nervous system (CNS) (37). The TPH1 gene is located 
on chromosome 11p15.3-p14. Several studies showed no asso-
ciation between PD and the TPH1 218A/C SNP in intron 7 (38-
40). The human TPH2 gene is located on chromosome 12q21. 
A German sample found no association between the disorder 
and the TPH2 SNPs rs4570625 and rs4565946 or their haplo-
types (41). A study with a Korean sample, however, described a 
significant difference in rs4570625 allele frequency between 
patients and normal controls and showed this may have a gen-
der-dependent effect on susceptibility to PD (42). A study of Es-
tonian female patients with PD also observed an association 
with rs1386494 (43).
  The effects of serotonergic neurotransmission are mediated by 
at least 18 different serotonin receptors (5-HTR). Table 1 shows 
many of the studies that have produced conflicting results about 
the relationship between 5-HTR and PD. 
  The human serotonin transporter (5-HTT), a critical regula-
tor of serotonergic function and the initial target of antidepres-
sant drugs, is encoded by a single-copy gene (SLC6A4) located 
on chromosome 17q12. A 44-bp length variation in its upstream 
regulatory region (5-HTTLPR) modulates 5-HTT gene transcrip-
tion, with a functional impact on serotonin transporter activity. 
While one study of an Estonian sample reported an association 
between PD and the 5-HTTLPR long allele (39), most studies, 
with samples from other populations, have observed no associ-
ation between 5-HTTLPR and PD (44). One meta-analysis found 
no statistically significant association between 5-HTTLPR and 
PD (45). Recent evidence, however, suggests carriers of the 5- 
HTTLPR short allele might suffer from more severe panic and 
depressive symptoms (46) and that variants other than 5-HT-
TLPR might associate with PD (47). A functional polymorphism 
in the 5-HTT gene, which alters the balance of the two polyade-
nylation forms of 5-HTT (rs3813034), may be such a PD risk 
factor (48).
Monoamine oxidase (MAO) 
MAO is a mitochondrial enzyme that catalyzes the degradation 
of several biogenic amines intracellularly. The human gene en-
Table 1. Genetic studies on serotonergic receptors in panic disorder
Receptors Author Year published Result
5-HT1A Rothe C et al.
Huang YY et al.
Hettema JM et al.
Inada Y et al.
Strug LJ et al.
2004
2004
2008
2003
2010
Associated
Associated
N/A
N/A
N/A
5-HT2A Inada Y et al.
Maron E et al.
Yoon HK et al.
Fehr C et al.
Rothe C et al.
Martinez-Barrondo S et al.
2003
2005
2008
2001
2004
2005
Associated
 Associated
 N/A*
N/A
N/A 
N/A
5-HT2C Deckert J et al.
Inada Y et al.
2000
2003
Associated
†
N/A
5-HT3A Mizuta N et al. 2008 N/A
*Only associated with panic symptom severity; 
†Only in female patients. 5-HT, 5- 
hydroxytryptamine; N/A, not associated.Na H-R, et al.  •  The Genetic Basis of Panic Disorder
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coding MAOA is located on chromosome Xp11.3. Among its 
several polymorphisms, MAOA gene-linked polymorphic re-
gions (MAOA-LPR, MAOA-uVNTR) modulate the MAOA gene’s 
transcriptional activity and gender-specifically influence cere-
brospinal fluid 5-hydroxyindoleacetic acid concentrations (49). 
A study found the functionally-more-active, longer alleles (3.5, 
4, and 5) significantly associated with PD in female subgroups 
of the study’s German and Italian patients (50). However, a study 
of a Columbian family sample detected no genetic linkage or 
association between the functional promoter polymorphism in 
the MAOA gene and PD (51).
Cholecystokinin (CCK)
The gastrin-like neuropeptide, CCK neuro-modulator, is one of 
the most abundant neurotransmitter peptides in the brain. CCK 
plays an important role in PD’s neurobiology, in both humans 
and animals, via interaction with dopamine and other neu-
rotransmitters (52). CCK receptor agonists, such as the carboxy-
terminal tetrapeptide of CCK-4, provoke panic attacks with sig-
nificantly greater efficacy in patients than they do in controls. 
  The human CCK gene is on the short arm of human chromo-
some 3. An initial study showed a positive association between 
PD and the promoter variant (-36C > T; rs1799923) in the CCK 
gene (53), but others did not replicate the results (54, 55). One 
study described the protective effects of the promoter variant 
(-36C > T; rs1799923) and an intron 1 polymorphism (IVS1–7C 
> G; rs754635) in the CCK gene against PD (56).
  CCK receptors differentiate into two subtypes, CCK A recep-
tor (CCK-AR) and CCK B receptor (CCK-BR), based on their af-
finities for a structurally- and functionally-related peptide fami-
ly. CCK-BR is widely distributed throughout the CNS, whereas 
CCK-AR is only found in circumscribed brain regions (57). The 
CCK-AR gene has been mapped to chromosome 4p15.2–15.1, 
which encompasses the dopamine D5 gene locus (58). Associa-
tion studies on polymorphisms of the CCK-AR gene provided 
ambiguous results regarding the association between PD and 
CCK-AR -81A/G and -128G/T promoter polymorphisms in a 
Japanese sample (59) and negative findings regarding a poly-
morphism in the 3’-untranslated region of the CCK-AR gene and 
the PstI polymorphism in the boundary between intron 1 and 
exon 2 of the CCK-AR gene (60, 61). Another study described a 
two-marker haplotype (rs1800855/rs1800857) in the CCK-AR 
Table 2. Genetic studies on other brain systems that may be associated with panic disorder
System  Substrate Author Year published Result
Norepinephrine Transporter
Transporter
Sand PG et al.
Lee YJ et al. 
2002
2005
N/A
N/A
Dopamine DRD1
DRD4  
Transporter
Maron E et al.
Hamilton SP et al.
†
Hamilton SP et al.
†
2005
2000
2000
Associated
N/A
N/A
GABA                        GAD
  
                                GABAR
 
 
 
                                GABAT
GAD1
GAD2
GABRA1-5
GABRB1
GABRB3
GABRG2
SLC6A1
Hettema JM et al.
Hettema JM et al.
Crowe RR et al.
Kobayashi Y et al.
Kobayashi Y et al.
Sand PG et al.
Myhsok B et al.
2006
2006
1997
2007
2007
2000
2009
Associated*
N/A
N/A
N/A
N/A
N/A
Associated
 Nucleoside               Adenosine
   
ADORA1
ADORA2A
ADORA2A
ADORA2A
Deckert J et al.
Yamada K et al. 
Lam P et al.
Hamilton SP et al.
1998
2001
2005
2004
N/A
N/A
N/A
Associated
NPY NPY, NPY Y1 or Y2
NPY Y5 promoter region 
NPY Y5 promoter region
Domschke K et al.
‡
Domschke K et al.
‡,§
Lindberg C et al.
2008
2008
2006
N/A
Associated
N/A
BDNF Otowa T et al.
Shimizu E et al.
Lam P et al.
2009
2005
2004
N/A
N/A
N/A
Angiotensin Shimizu E et al.
Olsson M et al.
Bandelow B et al.
Erhardt A et al.
2004
2004
2007
2008
N/A
N/A
N/A
N/A
Hormonal system       HPA axis
 
 
                                sexual hormones
 
CRHR1
CRHR2 promoter region of GAL
CRHR2 promoter region of GAL
ESR1 progesterone receptor
ESR1 progesterone receptor 
Tharmalingam S et al.
Hodges LM et al.
Unschuld PG et al.
Sand PG et al.
Ho HP et al.
||
2006
2009
2008
2002
2004
N/A
N/A
Associated
N/A
Associated
*tentatively associated; 
†same study; 
‡same study, 
§effect originating from the subgroup of female patients, particularly with concurrent agoraphobia; 
||association only in female 
patients. N/A, not associated; GAD, glutamate decarboxylase; GABA, γ-aminobutyric acid; GABRA, GABA receptor A; GABRB, GABA receptor B; GABRG, GABA receptor G; 
GABAT, GABA transporter; NPY, neuropeptide Y; NPY Y, neuropeptide Y receptor; BDNF, brain-derived neurotrophic factor; DRD, dopamine receptor; ADORA, adenosine receptors; 
HPA axis, hypothalamic-pituitary-adrenal stress axis; CRHR, corticotrophin releasing hormone receptor; GAL, Galanin; ESR1, estrogen receptor 1 gene.Na H-R, et al.  •  The Genetic Basis of Panic Disorder
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gene as protective against PD in women (56). The gene for CCK-
BR, which contains a 1,356-bp open reading frame comprising 
five exons interspersed with four introns, has been located on 
chromosome 11p15.4 (62). The long alleles of the CCK-BR com-
puted tomography repeat polymorphism showed a significant 
association with PD in two Caucasian samples (55, 60) but not 
in Asian or in other Caucasian samples (54, 63, 64). A missense 
mutation in the extracellular loop of exon 2 (1550 G > A, Val125 > 
Ile) of CCK-BR showed no association with PD in a Japanese 
sample (65). 
Other candidate systems 
Table 2 presents other studies on genetic effects regarding PD. 
A non-monoaminergic candidate system for association with 
PD is the GABA (γ-aminobutyric acid) neurotransmitter system. 
GABA is the most important inhibitory neurotransmitter, and 
GABAA receptor is the prime target of the anxiolytic benzodiaz-
epines. However, there have been conflicting results regarding 
the GABA system’s genetic effects on PD, including glutamate 
decarboxylase (GAD), the GABA receptor, and the GABA trans-
porter.
  Adenosine, the purine nucleoside, acts as another important 
inhibitory neuromodulator besides GABA. There have also been 
conflicting results regarding several adenosine receptors (ADO-
RA) associations with PD. 
  Reportedly, neuropeptide Y (NPY) is involved in the patho-
physiology of anxiety and of PD in particular. There have been 
conflicting results regarding associations with PD.
  Brain-derived neurotrophic factor (BDNF) acts on certain 
neurons of the CNS, particularly serotonergic neurons, helping 
to support the survival of existing neurons and to encourage the 
growth and differentiation of new neurons and synapses. How-
ever, recent research has shown BDNF does not show genetic 
effects in regard to PD. The neuropeptide angiotensin is involved 
in the regulation of respiration, which has been suggested as a 
key mechanism in the development of panic attacks. However, 
the angiotensin system does not show genetic effects regarding 
PD, either. Table 2 shows selected BDNF and angiotensin results.
  PD studies on genes related to the hypothalamic-pituitary-
adrenal (HPA) axis have had negative results. Other studies have 
focused on genes coding for sexual hormones, because of the 
marked gender difference in PD prevalence. Galanin (GAL), in-
volved in the hypothalamic-hypophysiotropic signaling pro-
cess, is co-secreted with luteinizing hormone-releasing hormone 
(LHRH), possibly acting as an estrogen mediator. The promoter 
region of GAL has been suggested as having genetic effects re-
garding PD.  
Genome-wide association study (GWAS)
Since the first GWAS saw publication in March 2005 (66), re-
searchers have used GWAS to identify associations between ge-
netic loci-related traits and diseases. In 2009, the first GWAS of 
PD was published. It examined 200 Japanese patients and the 
same number of controls, using the GeneChip Human Mapping 
500 K Array Set. The authors reported two findings regarding 
loci that reached significance using stringent statistical thresh-
olds (i.e., P values < 5 × 10
-8). One of these loci lies within an in-
tron of the PKP1 gene, which encodes plakophilin 1, a protein 
involved in desmosome formation, and which, when mutated, 
leads to dermatologic syndromes in humans. The other locus 
lies within an intron of ANO2, which encodes anoctamin 2, a 
transmembrane protein that researchers recently found to func-
tion as a calcium-activated chloride channel in the olfactory epi-
thelium. These researchers conducted a second replication anal-
ysis of PD, examining 558 Japanese patients and 566 controls 
using the DigTag2 assay and reported this analysis in 2010 (67). 
They tested 32 markers in the replication sample. In their results, 
they found no significant association, after correcting for multi-
ple testing. However, they observed a difference at the nominal 
allele P value, < 0.05, for two SNPs (rs6733840 and rs132617). 
They also conducted haplotype analyses of SNPs in the APOL3 
and CLU genes. However, no results showed any significant as-
sociation with PD for these genes. If studies find specific GWAS 
genes underlying PD, this might alter the way psychiatrists un-
derstand PD’s biology, and researchers and clinicians might ap-
proach anxiety disorders from a new viewpoint. Replication stud-
ies on reported variants and further studies with larger sample 
sizes are needed.
 
CONSIDERATIONS IN THE GENETIC STUDIES OF 
PANIC DISORDER
Although studies have achieved tremendous results regarding a 
genetic basis for PD so far, researchers have not reached a clear 
conclusion. Linkage analyses have suggested that several chro-
mosomal regions associate with PD, but they have not yet iden-
tified a major gene for PD. Here, we discuss several limitations 
of genetic studies of PD, including considerations of current di-
agnostic problems with the DSM-IV criteria for PD. 
 
Small sample size
A small sample size, typically fewer than 200 patients, raises the 
problem of a lack of statistical power. It seems to be one of the 
reasons for inconsistent results. 
Gender and ethnic specificity 
PD is approximately twice as prevalent in women as in men. Sev-
eral studies suggest a gender-specific difference in the genetic 
susceptibility to PD. Three independent studies reported an as-
sociation between PD and the high-activity COMT 158val allele 
in female patients (26, 28, 29). In addition, studies have observed 
associations between PD and the rs1386494 SNP of TPH2 (43) Na H-R, et al.  •  The Genetic Basis of Panic Disorder
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and between PD and MAOA gene variations (50), but only in the 
female patient subgroups. Furthermore, a meta-analysis showed 
PD’s ethnic heterogeneity (35). Researchers have observed dif-
ferent associations between COMT and PD in Caucasian sam-
ples versus in Asian samples, showing PD associated with the 
COMT 158val allele (28, 29, 68) and the COMT 158met allele (27, 
30), as the respective major alleles. Thus, future studies should 
consider ethnicity.
Gene-gene interaction and gene-environment interaction 
Genetic complexity has a significant influence on PD, since it 
reflects the additive or interactive effects of multiple loci with 
small individual effects. Some preliminary evidence suggests 
gene-gene interactions. A study described a nominally signifi-
cant interaction between the functional 5-HTR1A 1019C/G and 
COMT (472G/A = V158M) polymorphisms in PD (69). Also, 
gene-environment interactions should be considered in the 
etiology of PD. Researchers have observed significant associa-
tions between caffeine-induced anxiety and the ADORA2A poly-
morphism (70-72). A study reported a significant interaction 
between levels of childhood emotional (or physical) maltreat-
ment and a serotonin transporter variant with regard to anxiety 
sensitivity (73), which clinicians consider a risk phenotype for 
PD.
Multiple phenotypes 
Other factors accounting for the data inconsistency might relate 
to PD’s phenotypic complexity; psychiatrists currently regard 
the definitions of adequate phenotypes and intermediate phe-
notypes as matters for discussion. The current psychiatric diag-
nostic systems, such as the DSM-IV, are not clearly optimal for 
gene studies’ purposes. In the large Virginia twin sample, Hette-
ma et al. (13) found that genetic and environmental influences 
on anxiety disorders were not isomorphic with the clinically-
defined categories. Molecular genetic studies have supported 
the idea that genetic effects regarding PD transcend diagnostic 
boundaries (16, 21). Smoller et al. (21) found some evidence of 
linkage to a locus on chromosome 10q for a phenotype compris-
ing PD and other anxiety disorders. In another linkage analysis, 
Kaabi et al. (16) observed a significant linkage between chro-
mosome 4q and a phenotype comprising PD, agoraphobia, so-
cial phobia, and specific phobia. In addition, several candidate 
genes (e.g., COMT, MAOA) have shown associations with PD 
and phobic anxiety (27, 28, 50, 68). Reportedly the glutamic acid 
decarboxylase 1 (GAD1) gene shows an association with a ge-
netic liability underlying PD, generalized anxiety disorder, pho-
bias, major depressive disorder, and the anxiety-related person-
ality trait of neuroticism (74). Notably, researchers have found 
the strongest evidence of linkage when using phenotype defini-
tions broadened beyond the DSM-IV criteria’s boundaries of 
diagnosis. Studies encountered strong evidence for the 13q lo-
cus when defining the phenotype as a syndrome including PD 
and several other medical conditions -mitral valve prolapse, se-
rious headaches, and/or thyroid problems (22, 24). In another 
study, on multiplex Icelandic families, Thorgeirsson et al. (20) 
observed a genome-wide significant Lod score of 4.18, on chro-
mosome 9q, for a phenotype that included comorbid anxiety 
disorders. In the largest linkage analysis to date, Fyer et al. (15) 
reported a genome-wide significant linkage to 15q, using a broad 
panic phenotype that included sporadic and limited-symptom 
panic attacks in addition to PD.
  Personality traits might have important correlations to PD, as 
well. One personality trait, introversion, is characterized by low 
levels of sociability, high levels of arousal, and a relatively low 
propensity to experience positive emotions. Another trait, neu-
roticism, reflects negative affectivity or the tendency to experi-
ence negative emotions (anxiety, sadness, anger). Introversion 
(low extraversion) and neuroticism have an estimated heritabil-
ity of 0.30-0.50, which is elevated for individuals with PD. These 
traits may underlie PD and comorbid major depression, as well 
(75). In addition, harm avoidance, which comprises fearful, so-
cially inhibited, easily tired, and pessimistic tendencies, has also 
been implicated in PD. High harm avoidance is frequently ob-
served among patients with PD (76).
  The temperamental profile known as behavioral inhibition 
(BI) has been also implicated as a familial and developmental 
risk factor for PD. BI is observable in laboratory-based assess-
ments as early as infancy. It consists of a stable tendency to be 
cautious, quiet, and behaviorally restrained in situations of nov-
elty. Longitudinal and cross-sectional studies have supported 
the idea that BI is a developmental risk factor for PD (77, 78), so-
cial phobia (79), and other anxiety disorder symptomatologies 
(77, 80, 81). A series of studies have demonstrated elevated BI 
among offspring of parents with PD, with or without agorapho-
bia (82, 83). Neurobiological correlates of BI suggest sympathet-
ic and HPA axis activation, right frontal cortical activation, and 
amygdala hyper-reactivity to novelty (84, 85). Genetic associa-
tion studies have implicated several genes, including cortico-
trophin releasing hormone gene (86) and serotonin transporter 
(SLC6A4), which may influence the BI phenotype (87).
CONCLUSION
To identify specific genes involved in PD has been challenging 
because of PD’s genetic and phenotypic complexity. GWAS rep-
lications with large samples, controlling for gender and ethnici-
ty, are required. In addition, researchers conducting genetic in-
vestigations of PD should consider broad panic-relevant symp-
toms, including panic syndromes. Neuroimaging phenotypes 
may supplement the deficit in current genetic studies. We ex-
pect progress in the treatment of PD through deepening psy-
chiatric knowledge regarding the genetic basis for this illness. Na H-R, et al.  •  The Genetic Basis of Panic Disorder
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AUTHOR SUMMARY
The Genetic Basis of Panic Disorder
Hae-Ran Na, Eun-Ho Kang, Jae-Hon Lee and Bum-Hee Yu
Panic disorder is one of the chronic and disabling anxiety disorders. There has been evidence for either genetic heterogeneity or 
complex inheritance, with environmental factor interactions and multiple single genes, in panic disorder’s etiology. However, to 
date no candidate gene association studies have established specific loci. Increasing evidence suggests genes underlying panic 
disorder overlap, transcending current diagnostic boundaries. In addition, an anxious temperament and anxiety-related personality 
traits may represent intermediate phenotypes that predispose to panic disorder. Future research should focus on broad phenotypes, 
defined by comorbidity or intermediate phenotypes. Genome-wide association studies in large samples, studies of gene-gene and 
gene-environment interactions, and pharmacogenetic studies are needed.